Creating a culture of shared data

Accelerating research to the bedside

Next generation sequencing identifies smoldering multiple myeloma patients with a high risk of disease progression

The Innovative Medicines Initiative

Daratumumab for patients with multiple myeloma

Venetoclax plus rituximab for patients with relapsed / refractory CLL

Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone for multiple myeloma

Multiple myeloma analysis from ASH 2017

Multiple myeloma highlights from ASH 2017

ASH 2017: Immunotherapy for multiple myeloma

Edoxaban versus dalteparin for venous thromboembolism associated with cancer

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in multiple myeloma